

Can FMR1 CGG repeat lengths predict the outcome in ICSI cycles?

Ebru Cogendez¹, Enis Ozkaya¹, Aylin Çakıroğlu Eser¹, Meryem Eken¹, Ali Karaman²

¹Department of Obstetrics and Gynecology, Health Sciences University, Zeynep Kamil Women's and Children's Diseases Training and Research Hospital, Istanbul, Turkey

²Department Of Medical Genetics, Health Sciences University Zeynep Kamil Women And Children's Diseases Training And Research Hospital, Istanbul, Turkey

ABSTRACT

Objectives: The aim of this study was to assess relationship between CGG repeat lengths and ovarian reserve and response to controlled ovarian stimulation (COH).

Material and methods: This prospective cohort study was carried out on patients (n = 49) who were admitted to the *in vitro* fertilization (IVF) clinic of the Zeynep Kamil Women's and Children's Diseases Training and Research Hospital, University of Health Sciences. Women under 40 years of age with premature ovarian insufficiency underwent genetic analysis to determine CGG repeat lengths. Ovarian reserve was assessed for each participant and participants underwent ovarian hyperstimulation and intracytoplasmic sperm injection (ICSI) cycle. Relationships between ovarian reserve, cycle outcome and CGG repeat lengths were assessed. Variables including fertility assessment including ovarian reserve tests [Follicle stimulating hormone (FSH), Luteinizing hormone (LH), Estradiol (E2), Prolactin (PRL), Thyroid stimulating hormone (TSH), Antimullerian hormone (AMH), antral follicle count (AFC) tests] and some IVF cycle characteristics were assessed in relation to number of CGG repeat numbers.

Results: None of the ovarian reserve tests and cycle characteristics was found to be correlated with CGG repeat lengths. Comparison of ovarian reserve tests and cycle characteristics revealed no difference between groups of women with CGG repeat length > 55 and CGG repeat length ≤ 55. Antimullerian hormone (AMH) was a significant predictor for cycle cancellation (AUC = 0.779, P = 0.008). AMH level > 0.035 was found to be the optimal cut off value to predict cycles reaching to embryo transfer with 71% sensitivity and 85% specificity. The rate of cycle cancellation was 71% in cases with AMH ≤ 0.035 whereas it was 20% in cases with AMH > 0.035 (p = 0.001). No difference was determined between groups with and without cycle cancellation in terms of CGG repeat lengths (55.3 vs 53.9, p = 0.769). Among cycles reaching to embryo transfer stage, 3 (13.6%) pregnancies were achieved.

Conclusions: Our data showed no relationship between CGG repeat lengths and ovarian reserve and response to controlled ovarian stimulation. This data also showed that no clinical difference between FMR gene mutation related POI and other etiologies.

Key words: CGG repeat length; fragile X; premature ovarian insufficiency; ICSI

Ginekologia Polska 2022; 93, 9: 735–741

INTRODUCTION

Premature ovarian insufficiency (POI) is seen in approximately 1% of the general female population before the age of 40 [1]. Although the main cause of this disease is unknown, common etiologies include genetic causes [2–6] and autoimmune diseases [7–9]. Among all the genetic causes, Fragile X is the most frequently blamed for this disorder. The premutation allele interval (55–200 CGG rep-

etition interval) is important because of the risk of POI and the risk of being transmitted as a full mutation to subsequent generations [10]. Shamilova et al. [11], reported that the < 28 CGG repeat interval is associated with anti-ovarian antibodies. Making this distinction in the etiology may be important in terms of affecting ovarian response to ovarian stimulation in POI patients in the future [11].

Corresponding author:

Ebru Cogendez

Department of Obstetrics and Gynecology, Health Sciences University, Zeynep Kamil Women's and Children's Diseases Training and Research Hospital, Istanbul, Turkey
 e-mail: ebrucogendez@gmail.com

Received: 13.01.2021 Accepted: 20.01.2021 Early publication date: 21.09.2021

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Many population studies have evaluated the relationship between FMR1 premutation (55–200) and POI. While a meta-analysis reported an increased risk of POI in pre-carriage carriers, particularly those of European origin [12], some researchers did not show a significant difference in populations.

FMR1 CGG repeat lengths are examined in four categories according to their stability: normal (< 44); intermediate or gray zone (45–54); premutation (55–200); and full mutation (> 200 repetitions) [13, 14]. FMR1 premutations are thought to account for ~5% of all POI cases [15]. The clinical significance of these ranges for ovarian function is highly controversial. Studies have investigated the relationship between FMR1 CGG repeat lengths in the normal range and the intermediate range (gray zone) and the presence of POI or low ovarian reserve. Some investigators reported increased frequency of POI with FMR1 CGG repeat alleles in the intermediate range [16, 17], while other investigators failed to demonstrate this association [18, 19]. In addition, some studies have reported a relationship between low-ovarian reserve and FMR1 CGG repeat alleles in the normal range [20, 21], whereas in other publications [22, 23] the low over-expression of the normal range FMR1 CGG alleles was reported. The relationship with the reserve has not been shown. There is no consensus on the effect of CGG repeat lengths in the normal and intermediate range on ovarian reserve.

Objectives

Normally, only premutations have a definite relationship with POI, but some studies have shown that POI can develop in normal or gray zone cases. Discussion continues in the literature on the exact relationship between the detection of CGG repeat intervals in the normal and intermediate range with POI, unlike premutation. As we know, 5–10% spontaneous pregnancy can be seen in patients with premature ovarian failure. In patients with normal AMH and AFC, it will be possible to direct the patients in terms of clinical follow-up by looking at the number of CGG repetitions instead of waiting for spontaneous pregnancy. In the light of these data, the aim of our study was to evaluate the relationship between FMR1 CGG repeat lengths and ovarian reserve and response to ovarian stimulation.

MATERIAL AND METHODS

Patient population

In order to evaluate the relationship between the number of CGG and ovarian reserve and ovarian response to stimulation, this prospective cohort study was carried out on patients (n = 49) who were admitted to the IVF clinic of the Zeynep Kamil Women's and Children's Diseases Training and Research Hospital, University of Health Sciences,

Istanbul with infertility between June 2017 and January 2018. This study was conducted in accordance with the Declaration of Helsinki. Approval for this study was obtained from the Institutional Review Board (2017/41). A written informed consent was obtained from all participants.

POI was diagnosed according to ESHRE criteria [24]; under 40 years; cases with oligo-amenorrhea for at least four months and with a high follicle stimulating hormone (FSH) level > 25 IU/L twice every four weeks. Although oocyte donation was reported as the first choice in WHO type III anovulatory patients, since oocyte donation program is not legal in our country, patients were directed to ART. All of these patients underwent initial fertility assessment, conventional fertility assessment include ovarian reserve tests (FSH, Luteinizing hormone (LH), Estradiol (E2), Prolactin (PRL), Thyroid stimulating hormone (TSH), Antimüllerian hormone (AMH) Antral follicle count (AFC) tests). Since the relationship between Fragile X carriage and POI is well known, Fragile-X permutation test was requested for all patients not only to reveal the cause of POI, but also because the presence of mutation could have significant effects for the patient and his/her family. Patients were referred to the genetic clinic of our hospital prior to controlled ovarian hyperstimulation (COH) cycle for Fragile X premutation screening.

To avoid multiple comparison statistical bias, only information regarding the initial stimulation cycle of each patient was included. The age of patients during stimulation was also recorded. Initial gonadotropin dose was calculated according to patients' age, AMH and number of antral follicles. Initial gonadotropin doses were between 300 and 450 IU/day (75–150 H LH was added to each case as gonadotropin in total dose). A flexible antagonist protocol was applied for inhibition of the premature LH surge during the COH cycle. For this purpose, when the dominant follicle reached a diameter of 13 mm, 0.25 mg Cetorelix (Cetrotide; Merck Serono, Switzerland) was started subcutaneously once a day in the morning. Ovulation was triggered with 250 µgr of recombinant hCG (Ovitrelle; Merck-Serono, Switzerland) subcutan was applied when at least one follicle diameter reached ≥ 18 mm. Oocyte aspiration was performed 36 hours after hCG injection under transvaginal ultrasound guidance. The number of mature oocytes obtained in response to stimulation was evaluated as a measure of ovarian response.

Fragile X evaluation was performed using a commercially available kit "Fragile X GScan Kit" (Gene Link-Hawthorne, NY, USA), a standard test procedure mentioned by Sherman et al in their 2005 study [25]. Fragile X genotyping was performed with a DNA sequencer (ABI-310 DNA Sequencer; Applied Biosystems, USA) for direct fluorescent PCR amplification of the CGG trinucleotide repeat region and fragment analysis.

FSH, E2 and AMH concentrations were evaluated by commercial experiment (Diagnostic System Laboratories Inc, Texas, USA) using enzyme-linked immunosorbent assay. All comparisons were performed per participant instead of cycle. The variation coefficients for these three tests were between 2.4% and 8.6%. Individuals with approximately 55–200 CGG repeats were considered premutation carriers. The primary aim of this study was to figure out any association between number of CGG repeat length and cycle outcome. The secondary outcome was to assess possible relationship between number of CGG repeat length and ovarian reserve markers.

Statistical analysis

The statistical analysis was performed with using the Statistical Package for the Social Sciences version 21.0 (SPSS Inc., Chicago, IL, USA). The continuous variables were expressed as the mean \pm standard deviation. The categorical variables were expressed as the number and percentage. Mann-Whitney U test was used for nonparametric data. Statistical significance was defined as $p < 0.05$.

RESULTS

None of the ovarian reserve tests and cycle characteristics was found to be correlated with CGG repeat length (Tab. 1). Comparison of ovarian reserve tests and cycle characteristics revealed that no difference between groups of women with CGG repeat lengths ≤ 55 and > 55 (Tab. 2). Comparison of groups with and without cycle cancellation did not show any significant difference between groups in terms of age ($p = 0.8$), FSH ($p = 0.06$), CGG repeat number ($p = 0.6$) and total antral follicle counts ($p = 0.2$) but serum AMH ($p = 0.007$) was significantly lower in group with cycle cancellation. AMH was a significant predictor for cycle cancellation (AUC = 0.779, $p = 0.008$). AMH level > 0.035 was found to be the optimal cut off value to predict cycles reaching to embryo transfer with 71% sensitivity and 85% specificity. AMH > 0.035 is associated with cycle cancellation [OR = 0.1, 95% CI (0.02–0.5, $p = 0.001$)]. The rate of cycle cancellation was 71% in cases with AMH ≤ 0.035 whereas it was 20% in cases with AMH > 0.035 ($p = 0.001$, Tab. 3). No difference was determined between groups with and without cycle cancellation in terms of CGG repeat lengths (55.3 vs 53.9,

$p = 0.769$). Among cycles reaching to embryo transfer stage 3 (13.6%) pregnancies were achieved.

DISCUSSION

The main reason for investigating triple CGG repeats on the FMR1 gene has been the prevention and/or diagnosis of psychiatric and/or neurological conditions that have historically been associated with extremely high triple re-expansion and full mutation (Fragile X syndrome > 200 CGG repetition) intervals [26, 27]. The current classification of CGG repetition extends to typical (normal), intermediate (gray zone), premutations, and full mutation, so it is based solely on a screening process for psychiatric and neurological risks. Therefore, these risk ranges have nothing to do with other potential risks associated with triple CGG repeats in the FMR1 gene, such as the risk for premature ovarian aging.

The aim of this study was to assess relationship between CGG repeated numbers and ovarian reserve and response to gonadotropin stimulation. Our data showed no relationship between CGG repeat lengths and ovarian reserve and response. This data also showed no clinical difference between FMR gene mutation related POI and other etiologies.

In studies of markers of ovarian function in populations, a relationship was found between the premutation carriers, which was largely based on the family history of fragile X syndrome and both FSH and AMH [28]. No correlation was found between medium number CGG repeats and POI. Therefore, a role of up to 55 repetitions for FMR1 CGG repeat sizes in the ovarian aging process can be questioned. Furthermore, the diagnostic study of women affected by POI shows a limited value for the assessment of normal and moderate FMR1 repeat size or for prognostic purposes in women at risk of developing POI [29]. Some cut off values for CGG repeat length have been proposed in the context of ovarian function, normal values were suggested to be between 26–34, whereas > 34 repetitions were considered to be high and < 26 repeat was considered to be low. These values were suggested to be associated with weaker embryo morphology and an accelerated decrease in functional ovarian reserve [30]. Tang et al. [31], evaluated the relationship between the number of CGG repeats in FMR1 in Chinese patients with POI and DOR. The authors found that the frequency of FMR1 premutation did not differ between

Table 1. Correlation between ovarian reserve tests and cycle characteristics with the number of CGG repeats

		Age [years]	FSH	LH	AMH	Total AFC	Total Gonadotropin dose	Stimulation day at oocyte trigger	Peak estradiol	Total oocyte number
CGG repeat #	Correlation coefficient (r)	-0.115	0.079	0.048	0.153	-0.009	-0.072	-0.106	0.282	0.258
	p value	0.437	0.595	0.751	0.413	0.949	0.625	0.638	0.228	0.203

FSH — follicle stimulating hormone; LH — luteinizing hormone; AMH — antimullerian hormone; AFC — antral follicle count

Table 2. Comparison of ovarian reserve tests and cycle characteristics between groups of women with CGG repeat lengths ≤ 55 and > 55

	Groups	Mean	Std. Deviation	p value
Age [years]	CGG ≤ 55	29.8	6.3	0.866
	CGG > 55	29.9	5.2	
FSH [mIU/mL]	CGG ≤ 55	37.7	35.4	0.867
	CGG > 55	31.6	33.8	
Estradiol [pg/mL]	CGG ≤ 55	42.2	42.6	0.810
	CGG > 55	40.3	52.7	
Progesterone [ng/mL]	CGG ≤ 55	0.4	0.5	0.031
	CGG > 55	0.5	0.2	
TSH [mIU/L]	CGG ≤ 55	1.7	1.09	0.652
	CGG > 55	1.7	0.7	
Prolactin [20 ng/mL]	CGG ≤ 55	15.4	9	0.702
	CGG > 55	17.2	9.7	
LH [mIU/mL]	CGG ≤ 55	18.1	17.5	0.982
	CGG > 55	17.1	20.06	
AMH [ng/mL]	CGG ≤ 55	0.4	0.8	0.724
	CGG > 55	0.8	2.1	
Total_AFC	CGG ≤ 55	6.09	4.01	0.484
	CGG > 55	5.4	4.3	
Total gonadotropin dose [IU]	CGG ≤ 55	3584.03	1493.7	0.765
	CGG > 55	3604.8	994.3	
Menstrual day at ovulation trigger	CGG ≤ 55	10.9	3.2	0.748
	CGG > 55	11.2	2.8	
Peak estradiol level [pg/mL]	CGG ≤ 55	673.3	435.3	0.274
	CGG > 55	967.5	359.01	
Total number of oocytes	CGG ≤ 55	0.7	0.8	0.497
	CGG > 55	1	0.8	
Total number of mature oocytes	CGG ≤ 55	0.4	0.5	0.572
	CGG > 55	0.6	0.5	

FSH — follicle stimulating hormone; TSH — thyroid stimulating hormone; LH — luteinizing hormone; AMH — antimullerian hormone; AFC — antral follicle count

Table 3. The rates of cycle cancellation of women with antimullerian hormone (AMH) ≤ 0.035 and AMH > 0.035

	AMH ≤ 0.035	AMH > 0.035	Total	p value
Uncancelled	10	12	22	P < 0.001
	29.4%	80%	44.9%	
Cancelled	24	3	27	P < 0.001
	70.6%	20%	55.1%	
Total	34	15	49	P < 0.001
	100.0%	100.0%	100.0%	

POI or DOR and normal menopausal controls; they reported that the most common CGG repeats were 29 and 30, and the repeat length for allele 2 had a secondary peak around 36–39 repeats. In addition, the researchers reported that mean FSH and AMH values did not show any association with different CGG repeats in both the POI and DOR groups [31].

In our study population, there was only one case with CGG repeat length of 2, among all the remaining cases the lowest number of repeat numbers was 38.

Whether the FMR1 CGG repeat length can be used clinically to predict IVF outcome is a controversial issue. In a study performed by Banks et al. [32], with 4690 fresh

transfer cycles, FMR1 CGG repeat lengths was associated with ART response; however, this relationship has been reported to be weak for use during clinical management [32]. The authors argued that CGG repeat lengths do not have a higher predictive ability beyond classical predictors such as age, AMH, FSH, AFC. Banks et al. [32], data reveals a possible role of FMR1 CGG repeat length in the normal zone in ovarian response but failed to demonstrate clinical significance as a predictor of ART results. In another study conducted by Fıçıcıoğlu et al. [33], they suggested that the triple repeat numbers of CGG can predict a reduced ovarian reserve before the onset of ovarian aging, and that in clinical practice CGG repeats can be used to predict premature ovarian aging (FSH > 12–50IU/mL) and ovarian reserve.

A recent study by Batiha et al. [34], evaluated the relationship between short CGG repeats (< 26; 26–34; > 34) and poor ovarian response. The researchers reported that CGG median allele sizes differed significantly between cases and controls, and poor ovarian responders carried shorter CGG repeats compared to healthy controls. The authors also noted that women with < 26 alleles showed twice as poor ovarian response as compared to controls. However, the authors also reported that they did not find a significant relationship between CGG repeats and ovarian reserve markers, similar to our study. The authors concluded that although low CGG repeats appeared to be associated with POR as a result of their study, the clinical use of FMR1 to predict ovarian response needs further research [34].

Lledo et al., [19] evaluated the results of oocyte donation cycle. The study cases were examined in three groups with CGG repeat lengths of 35–39 (n = 34), 40–45 CGG (n = 12) and > 45 CGG (n = 17) and the ovarian response was found to be similar between the groups. This study is the first to evaluate the ovarian response in subjects with a normal and intermediate repeat lengths. As a result of this study, the authors recommended that CGG repeats in the intermediate zone does not adversely affect the ovarian response, so fragile X genetic screening should not be taken into account in predicting ovarian response. In a study conducted by Rehnitz et al. [35], they evaluated the COH response in three groups as poor responder, normoresponder and hyperresponder, and divided the patients into six genotypes according to CGG repeat lengths. The authors reported that the ovarian response could be adversely affected by low CGG alleles. They even argued that this poor ovarian response associated with a low CGG allele might be impaired during folliculogenesis independent of stimulation.

In a study conducted by Gustin et al. [36], with 566 patients, it was found that the relationship between CGG repeat length and AMH changes with age in an analysis using a multivariate regression model. In our study mean age of

whole study population was 29 years and our data analysis revealed no association with AMH level and CGG repeat length. We used AMH level to be reference predictor for cycle outcome and AMH significantly predicted cycles reaching to embryo transfer among cycles with high rate of cancellation, overall cancellation rate was 55.1% in all the study groups. In a past study by Pastore et al. [37], the cycle characteristics of seventy-nine women with a diagnosis of low ovarian reserve and no family history of fragile X syndrome were evaluated. As a result of the study, the authors reported that women with a CGG repeat length ≥ 35 had a higher rate of follicular loss starting at later ages.

The impact of smaller repeats at the boundary of premenarche and normal is less clear. Eslami et al. [38], compared the FMR1 CGG repeat lengths with the intermediate and premutation group in a study they included the POI, DOR, and healthy control group. In the study, the frequency of premenarche was found to be higher in patients with POI and DOR than in control patients; intermediate allele frequency was similar between groups. Based on the results of the study, the authors concluded that FMR1 CGG repeat alleles in the intermediate zone do not pose a high risk for POI and DOR.

Ranisavljevic et al. [39], investigated that ovarian response to controlled ovarian stimulation in premenarche and full mutation carriers and compared the clinical results. They reported that significantly higher FSH doses were needed for ovarian stimulation in premenarche patients. However, the researchers found no correlation between the number of oocytes collected and the number of CGG repeats [39].

A current meta-analysis of Pastore [40] revealed no association within subcategories of normal repeat length (< 45 CGG) and IVF pregnancy rates. It was shown that, premenarche carriers (CGG 55–200) may have reduced success with IVF treatment than women with a normal CGG repeat length or a full mutation [40]. According to these cited researches, there is no consensus on this issue, majority of the investigations showed no predictive value of CGG repeat lengths and reproduction, while some showed lower number of repeats to be risk factor for poor outcome, on the other hand some showed higher repeat number may be responsible for poor response in IVF. For this reason, we conducted this prospective study, in our study, we included consecutive women diagnosed to have POI, major disadvantage of this study was small sample size and lack of data regarding other etiologies of POI.

CONCLUSIONS

In conclusion, our study showed no relationship between CGG repeat lengths and ovarian response to ovarian stimulation. Despite the small number of patients, the results of our study are consistent with the current literature.

Conflicts of interest

All authors declare that they have no conflict of interest.

REFERENCES

- Kunicki M, Rudnicka E, Skórska J, et al. Insulin resistance indexes in women with premature ovarian insufficiency - a pilot study. *Ginekol Pol.* 2018; 89(7): 364–369, doi: [10.5603/GP.a2018.0062](https://doi.org/10.5603/GP.a2018.0062), indexed in Pubmed: [30091445](https://pubmed.ncbi.nlm.nih.gov/30091445/).
- Falorni A, Minarelli V, Eads CM, et al. A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency. *Panminerva Med.* 2014; 56(4): 245–261, indexed in Pubmed: [25288327](https://pubmed.ncbi.nlm.nih.gov/25288327/).
- Uhlenhaut NH, Treier M, Foxl2 function in ovarian development. *Mol Genet Metab.* 2006; 88(3): 225–234, doi: [10.1016/j.ymgme.2006.03.005](https://doi.org/10.1016/j.ymgme.2006.03.005), indexed in Pubmed: [16647286](https://pubmed.ncbi.nlm.nih.gov/16647286/).
- Depmann M, Eijkemans MJC, Broer SL, et al. Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study. *Hum Reprod.* 2016; 31(7): 1579–1587, doi: [10.1093/humrep/dew112](https://doi.org/10.1093/humrep/dew112), indexed in Pubmed: [27179263](https://pubmed.ncbi.nlm.nih.gov/27179263/).
- Davies P, Connor E, MacKenzie J, et al. Spontaneous recovery of ovarian function in an adolescent with galactosemia and apparent Premature ovarian insufficiency. *J Pediatr Adolesc Gynecol.* 2015; 28(4): e101–e103, doi: [10.1016/j.jpag.2014.09.003](https://doi.org/10.1016/j.jpag.2014.09.003), indexed in Pubmed: [26024933](https://pubmed.ncbi.nlm.nih.gov/26024933/).
- Hundscheid RD, Sisternans EA, Thomas CM, et al. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X pre-mutations. *Am J Hum Genet.* 2000; 66(2): 413–418, doi: [10.1086/302774](https://doi.org/10.1086/302774), indexed in Pubmed: [10673300](https://pubmed.ncbi.nlm.nih.gov/10673300/).
- Coulam CB. The prevalence of autoimmune disorders among patients with primary ovarian failure. *Am J Reprod Immunol.* 1983; 4(2): 63–66, doi: [10.1111/j.1600-0897.1983.tb00254.x](https://doi.org/10.1111/j.1600-0897.1983.tb00254.x), indexed in Pubmed: [6650708](https://pubmed.ncbi.nlm.nih.gov/6650708/).
- Silva CA, Yamakami LYS, Aikawa NE, et al. Autoimmune primary ovarian insufficiency. *Autoimmun Rev.* 2014; 13(4-5): 427–430, doi: [10.1016/j.autrev.2014.01.003](https://doi.org/10.1016/j.autrev.2014.01.003), indexed in Pubmed: [24418305](https://pubmed.ncbi.nlm.nih.gov/24418305/).
- La Marca A, Marzotti S, Brozzetti A, et al. Italian Addison Network. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. *J Clin Endocrinol Metab.* 2009; 94(10): 3816–3823, doi: [10.1210/jc.2009-0817](https://doi.org/10.1210/jc.2009-0817), indexed in Pubmed: [19622621](https://pubmed.ncbi.nlm.nih.gov/19622621/).
- Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. *JAMA.* 2004; 291(4): 460–469, doi: [10.1001/jama.291.4.460](https://doi.org/10.1001/jama.291.4.460), indexed in Pubmed: [14747503](https://pubmed.ncbi.nlm.nih.gov/14747503/).
- Shamilova NN, Marchenko LA, Dolgushina NV, et al. The role of genetic and autoimmune factors in premature ovarian failure. *J Assist Reprod Genet.* 2013; 30(5): 617–622, doi: [10.1007/s10815-013-9974-4](https://doi.org/10.1007/s10815-013-9974-4), indexed in Pubmed: [23504400](https://pubmed.ncbi.nlm.nih.gov/23504400/).
- Tosh D, Rao KL, Rani HS, et al. Association between fragile X premutation and premature ovarian failure: a case-control study and meta-analysis. *Arch Gynecol Obstet.* 2014; 289(6): 1255–1262, doi: [10.1007/s00404-014-3145-4](https://doi.org/10.1007/s00404-014-3145-4), indexed in Pubmed: [24452737](https://pubmed.ncbi.nlm.nih.gov/24452737/).
- Maddalena A, Richards CS, McGinniss MJ, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. *Genet Med.* 2001; 3(3): 200–205, doi: [10.1097/00125817-200105000-00010](https://doi.org/10.1097/00125817-200105000-00010), indexed in Pubmed: [11388762](https://pubmed.ncbi.nlm.nih.gov/11388762/).
- Barros F, Carvalho F, Barros A, et al. Premature ovarian insufficiency: clinical orientations for genetic testing and genetic counseling. *Porto Biomed J.* 2020; 5(3): e62, doi: [10.1097/j.pbj.0000000000000062](https://doi.org/10.1097/j.pbj.0000000000000062), indexed in Pubmed: [33299945](https://pubmed.ncbi.nlm.nih.gov/33299945/).
- Murray A, Schoemaker MJ, Bennett CE, et al. Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. *Genet Med.* 2014; 16(1): 19–24, doi: [10.1038/gim.2013.64](https://doi.org/10.1038/gim.2013.64), indexed in Pubmed: [23703681](https://pubmed.ncbi.nlm.nih.gov/23703681/).
- Bodega B, Bione S, Dalprà L, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. *Hum Reprod.* 2006; 21(4): 952–957, doi: [10.1093/humrep/dei432](https://doi.org/10.1093/humrep/dei432), indexed in Pubmed: [16361284](https://pubmed.ncbi.nlm.nih.gov/16361284/).
- Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. *Hum Genet.* 2005; 117(4): 376–382, doi: [10.1007/s00439-005-1326-8](https://doi.org/10.1007/s00439-005-1326-8), indexed in Pubmed: [16078053](https://pubmed.ncbi.nlm.nih.gov/16078053/).
- Bennett CE, Conway GS, Macpherson JN, et al. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. *Hum Reprod.* 2010; 25(5): 1335–1338, doi: [10.1093/humrep/deq058](https://doi.org/10.1093/humrep/deq058), indexed in Pubmed: [20228389](https://pubmed.ncbi.nlm.nih.gov/20228389/).
- Lledo B, Guerrero J, Ortiz JA, et al. Intermediate and normal sized CGG repeat on the FMR1 gene does not negatively affect donor ovarian response. *Hum Reprod.* 2012; 27(2): 609–614, doi: [10.1093/humrep/der415](https://doi.org/10.1093/humrep/der415), indexed in Pubmed: [22157911](https://pubmed.ncbi.nlm.nih.gov/22157911/).
- Pastore LM, Young SL, Baker VL, et al. Elevated prevalence of 35–44 FMR1 trinucleotide repeats in women with diminished ovarian reserve. *Reprod Sci.* 2012; 19(11): 1226–1231, doi: [10.1177/1933719112446074](https://doi.org/10.1177/1933719112446074), indexed in Pubmed: [22581803](https://pubmed.ncbi.nlm.nih.gov/22581803/).
- Gleicher N, Weghofer A, Oktay K, et al. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test? *Acta Obstet Gynecol Scand.* 2009; 88(9): 1024–1030, doi: [10.1080/00016340903171058](https://doi.org/10.1080/00016340903171058), indexed in Pubmed: [19642041](https://pubmed.ncbi.nlm.nih.gov/19642041/).
- Schuffreider A, McQueen DB, Lee SM, et al. Diminished ovarian reserve is not observed in infertility patients with high normal CGG repeats on the fragile X mental retardation 1 (FMR1) gene. *Hum Reprod.* 2015; 30(11): 2686–2692, doi: [10.1093/humrep/dev220](https://doi.org/10.1093/humrep/dev220), indexed in Pubmed: [26345686](https://pubmed.ncbi.nlm.nih.gov/26345686/).
- Morin SJ, Tiegs AW, Franasiak JM, et al. FMR1 gene CGG repeat variation within the normal range is not predictive of ovarian response in IVF cycles. *Reprod Biomed Online.* 2016; 32(5): 496–502, doi: [10.1016/j.rbmo.2016.02.009](https://doi.org/10.1016/j.rbmo.2016.02.009), indexed in Pubmed: [27013081](https://pubmed.ncbi.nlm.nih.gov/27013081/).
- Wittember L, Davies M, Anderson R, et al. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. *Hum Reprod.* 2016; 31(5): 926–937, doi: [10.1093/humrep/dew027](https://doi.org/10.1093/humrep/dew027), indexed in Pubmed: [27008889](https://pubmed.ncbi.nlm.nih.gov/27008889/).
- Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. *Genet Med.* 2005; 7(8): 584–587, doi: [10.1097/01.gim.0000182468.22666.dd](https://doi.org/10.1097/01.gim.0000182468.22666.dd), indexed in Pubmed: [16247297](https://pubmed.ncbi.nlm.nih.gov/16247297/).
- Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. *Fertil Steril.* 2007; 87(3): 456–465, doi: [10.1016/j.fertnstert.2006.09.004](https://doi.org/10.1016/j.fertnstert.2006.09.004), indexed in Pubmed: [17074338](https://pubmed.ncbi.nlm.nih.gov/17074338/).
- Tassanakijpanich N, Hagerman RJ, Worachotekamjorn J. Fragile X premutation and associated health conditions: A review. *Clin Genet.* 2021; 99(6): 751–760, doi: [10.1111/cge.13924](https://doi.org/10.1111/cge.13924), indexed in Pubmed: [33443313](https://pubmed.ncbi.nlm.nih.gov/33443313/).
- Spath MA, Feuth TB, Allen EG, et al. Intra-individual stability over time of standardized anti-Müllerian hormone in FMR1 premutation carriers. *Hum Reprod.* 2011; 26(8): 2185–2191, doi: [10.1093/humrep/der146](https://doi.org/10.1093/humrep/der146), indexed in Pubmed: [21576079](https://pubmed.ncbi.nlm.nih.gov/21576079/).
- Voorhuis M, Onland-Moret NC, Janse F, et al. Dutch Primary Ovarian Insufficiency Consortium. The significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal and intermediate range in women with primary ovarian insufficiency. *Hum Reprod.* 2014; 29(7): 1585–1593, doi: [10.1093/humrep/deu095](https://doi.org/10.1093/humrep/deu095), indexed in Pubmed: [24812319](https://pubmed.ncbi.nlm.nih.gov/24812319/).
- Gleicher N, Yu Y, Himaya E, et al. Early decline in functional ovarian reserve in young women with low (CGGn < 26) FMR1 gene alleles. *Transl Res.* 2015; 166(5): 502–507.e1, doi: [10.1016/j.trsl.2015.06.014](https://doi.org/10.1016/j.trsl.2015.06.014), indexed in Pubmed: [26209748](https://pubmed.ncbi.nlm.nih.gov/26209748/).
- Tang R, Yu Qi. The significance of FMR1 CGG repeats in Chinese women with premature ovarian insufficiency and diminished ovarian reserve. *Reprod Biol Endocrinol.* 2020; 18(1): 82, doi: [10.1186/s12958-020-00645-5](https://doi.org/10.1186/s12958-020-00645-5), indexed in Pubmed: [32787884](https://pubmed.ncbi.nlm.nih.gov/32787884/).
- Banks N, Patounakis G, Devine K, et al. Is FMR1 CGG repeat length a predictor of in vitro fertilization stimulation response or outcome? *Fertil Steril.* 2016; 105(6): 1537–1546.e8, doi: [10.1016/j.fertnstert.2016.02.011](https://doi.org/10.1016/j.fertnstert.2016.02.011), indexed in Pubmed: [26940792](https://pubmed.ncbi.nlm.nih.gov/26940792/).
- Fiçiocğlu C, Yildirim G, Attar R, et al. The significance of the number of CGG repeats and autoantibodies in premature ovarian failure. *Reprod Biomed Online.* 2010; 20(6): 776–782, doi: [10.1016/j.rbmo.2010.02.011](https://doi.org/10.1016/j.rbmo.2010.02.011), indexed in Pubmed: [20362512](https://pubmed.ncbi.nlm.nih.gov/20362512/).
- Batiha O, Shaaban ST, Al-Smadi M, et al. A study on the role of FMR1 CGG trinucleotide repeats in Jordanian poor ovarian responders. *Gene.* 2021; 767: 145174, doi: [10.1016/j.gene.2020.145174](https://doi.org/10.1016/j.gene.2020.145174), indexed in Pubmed: [33007370](https://pubmed.ncbi.nlm.nih.gov/33007370/).
- Rehnitz J, Alcoba DD, Brum IS, et al. FMR1 expression in human granulosa cells increases with exon 1 CGG repeat length depending on ovarian reserve. *Reprod Biol Endocrinol.* 2018; 16(1): 65, doi: [10.1186/s12958-018-0383-5](https://doi.org/10.1186/s12958-018-0383-5), indexed in Pubmed: [29981579](https://pubmed.ncbi.nlm.nih.gov/29981579/).

36. Gustin SLF, Ding VY, Desai M, et al. Evidence of an age-related correlation of ovarian reserve and FMR1 repeat number among women with „normal“ CGG repeat status. *J Assist Reprod Genet.* 2015; 32(11): 1669–1676, doi: [10.1007/s10815-015-0577-0](https://doi.org/10.1007/s10815-015-0577-0), indexed in Pubmed: [26409477](https://pubmed.ncbi.nlm.nih.gov/26409477/).
37. Pastore LM, McMurry TL, Williams CD, et al. AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level. *J Assist Reprod Genet.* 2014; 31(10): 1295–1301, doi: [10.1007/s10815-014-0276-2](https://doi.org/10.1007/s10815-014-0276-2), indexed in Pubmed: [24938362](https://pubmed.ncbi.nlm.nih.gov/24938362/).
38. Eslami A, Farahmand K, Totonchi M, et al. FMR1 premutation: not only important in premature ovarian failure but also in diminished ovarian reserve. *Hum Fertil (Camb).* 2017; 20(2): 120–125, doi: [10.1080/14647273.2016.1255356](https://doi.org/10.1080/14647273.2016.1255356), indexed in Pubmed: [27876427](https://pubmed.ncbi.nlm.nih.gov/27876427/).
39. Ranisavljevic N, Hess M, Castelli C, et al. Are ovarian response and pregnancy rates similar in selected FMR1 premutated and mutated patients undergoing preimplantation genetic testing? *J Assist Reprod Genet.* 2020; 37(7): 1675–1683, doi: [10.1007/s10815-020-01809-3](https://doi.org/10.1007/s10815-020-01809-3), indexed in Pubmed: [32483686](https://pubmed.ncbi.nlm.nih.gov/32483686/).
40. Pastore L, Christianson M, McGuinness B, et al. Does the FMR1 gene affect IVF success? *Reproductive BioMedicine Online.* 2019; 38(4): 560–569, doi: [10.1016/j.rbmo.2018.11.009](https://doi.org/10.1016/j.rbmo.2018.11.009).